These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 3901244

  • 1. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
    Scand J Haematol; 1985 Aug; 35(2):205-9. PubMed ID: 3901244
    [Abstract] [Full Text] [Related]

  • 2. Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
    Palva IP, Ala-Harja K, Almqvist A, Elonen E, Hallman H, Hänninen A, Ilvonen M, Isomaa B, Jouppila J, Järvenpää E.
    Eur J Haematol; 1993 Aug; 51(2):98-101. PubMed ID: 8370425
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
    [Abstract] [Full Text] [Related]

  • 4. Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1989 Nov; 43(5):385-8. PubMed ID: 2612611
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A, Holománová D, Mikulecký M, Mistrík M, Lipsic T, Steruská M.
    Neoplasma; 1993 Nov; 40(6):351-4. PubMed ID: 8289966
    [Abstract] [Full Text] [Related]

  • 6. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Nov; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 7. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM, Leong T, Lenhard RE, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA.
    Cancer; 1999 Sep 15; 86(6):957-68. PubMed ID: 10491521
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
    Steinke B, Busch FW, Stapelfeld S, Ostendorf P, Waller HD.
    Dtsch Med Wochenschr; 1984 Jun 29; 109(26):1015-9. PubMed ID: 6547386
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982).
    Bataille R, Souteyrand P, Sany J.
    Anticancer Res; 1984 Jun 29; 4(6):339-45. PubMed ID: 6517530
    [Abstract] [Full Text] [Related]

  • 14. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X, Monconduit M, Menard JF, Deshayes P, Grobois B, Tanguy A, Prevost E, Piguet H.
    Rev Rhum Mal Osteoartic; 1984 May 29; 51(5):263-7. PubMed ID: 6740189
    [Abstract] [Full Text] [Related]

  • 15. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group.
    Palva IP, Ahrenberg P, Ala-Harja K, Almqvist A, Hänninen A, Ilvonen M, Isomaa B, Jouppila J, Järvenpää E, Kilpi H.
    Eur J Haematol; 1989 Oct 29; 43(4):328-31. PubMed ID: 2583258
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F, Lein JM, Pavlovsky S, Becherini JO, Pileggi JE, Micheo EQ, Jait C, Musso A, Suárez A, Pizzolato M.
    Cancer Treat Rep; 1980 Jan 29; 64(1):73-9. PubMed ID: 6991106
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S, Writing Committee of the "Bologna 90" Clinical Trial.
    Haematologica; 2002 Sep 29; 87(9):934-42. PubMed ID: 12217805
    [Abstract] [Full Text] [Related]

  • 20. IgD multiple myeloma. A report of three cases.
    Martini R, Santini S, Bottari G.
    Minerva Med; 1996 Mar 29; 87(3):109-12. PubMed ID: 8668286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.